AbbVie Inc. (NYSE:ABBV) manufacturer of pharma products, is reporting third quarter earnings results on Friday 30th October 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 2.76 per share.
For the full year, analysts predict revenues of $ 45480.30 million, while looking forward to income of $ 10.42 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 50,000.00 million ~ $ 50,000.00 million, where as bottomline are predicted in a range of $ 10.35 ~ $ 10.45 per share
Click Here For More Historical Outlooks Of AbbVie Inc.
Previous Quarter Performance
AbbVie Inc. revealed income for the second quarter of $ 2.34 per share, from the revenue of $ 10,425.00 million. The quarterly earnings improved 3.54 percent while revenues improved 26.29 percent compared with the same quarter last year.
Street analysts expected AbbVie Inc. to report income of $ 2.19 per share on revenue of $ 10082.10 million for the second quarter. The bottom line results beat street analysts by $ 0.15 or 6.85 percent, at the same time, top line results outshined analysts by $ 342.90 million or 3.40 percent.
Stock Performance
Shares of AbbVie Inc. traded up $ 0.18 or 0.22 percent on Thursday, reaching $ 80.67 with volume of 8.67 million shares. AbbVie Inc. has traded high as $ 81.37 and has cracked $ 79.11 on the downward trend
According to the previous trading day, closing price of $ 80.67, representing a 28.68 % increase from the 52 week low of $ 62.55 and a 20.53 % decrease over the 52 week high of $ 101.28.
The company has a market capital of $ 142.37 billion and is part of the Healthcare sector and Drug Manufacturers – Major industry.
Recent Analyst recommendations
- On 16th October 2020, maintained by JPMorgan Chase & Co. at Overweight rating, with $ 120.00 target price.
- On 29th September 2020, initiated by Berenberg Bank at Hold rating, with $ 98.00 target price.
- On 2nd September 2020, maintained by Citigroup at Buy rating, with $ 105.00 target price.
Conference Call
AbbVie Inc. will be hosting a conference call at 9:00 AM eastern time on 30th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.abbvie.com
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçets diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenströms macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
